Represent

Lobbying
Lobbying by CIGNA Corporation

Lobbying Relationship

Client

CIGNA Corporation

More records

Lobbying firm

Invariant LLC

More records

Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.

Duration: January 1, 2008 to March 31, 2013

General Issues: Health Issues, Medicare/Medicaid, Pharmacy, Defense, Taxation/Internal Revenue Code, Labor Issues/Antitrust/Workplace, Insurance, Trade (Domestic & Foreign)

Spending: about $4,270,000 (But it's complicated. Here's why.)

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS),, Vice President of the U.S., Labor - Dept of (DOL), Office of Management & Budget (OMB), White House Office

Bills mentioned

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.CON.RES.71: Establishing the congressional budget for the United States Government...

Sponsor: Diane Black (R-Tenn.)

H.R.2050: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Joe Courtney (D-Conn.)

H.R.879: Ax the Tax on Middle Class Americans' Health Plans Act

Sponsor: Frank Guinta (R-N.H.)

S.2045: Middle Class Health Benefits Tax Repeal Act of 2015

Sponsor: Dean Heller (R-Nev.)

S.2075: American Worker Health Care Tax Relief Act of 2015

Sponsor: Sherrod Brown (D-Ohio)

H.R.2029: Consolidated Appropriations Act, 2016

Sponsor: Charlie Dent (R-Pa.)

H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...

Sponsor: John D. Dingell (D-Mich.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.2406: Healthcare Information Technology Enterprise Integration Act

Sponsor: Bart Gordon (D-Tenn.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

H.R.1424: A bill to provide authority for the Federal Government to purchase and...

Sponsor: Patrick J. Kennedy (D-R.I.)

H.R.6357: PRO(TECH)T Act of 2008

Sponsor: John D. Dingell (D-Mich.)

S.334: Healthy Americans Act

Sponsor: Ron Wyden (D-Ore.)

H.R.6049: Energy Improvement and Extension Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.7327: Worker, Retiree, and Employer Recovery Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.173: Middle Class Health Benefits Tax Repeal Act of 2017

Sponsor: Mike Kelly (R-Pa.)

S.58: Middle Class Health Benefits Tax Repeal Act of 2017

Sponsor: Dean Heller (R-Nev.)

H.R.3545: Overdose Prevention and Patient Safety Act

Sponsor: Tim Murphy (R-Pa.)

S.1850: Protecting Jessica Grubb's Legacy Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.4616: Employer Relief Act of 2018

Sponsor: Devin Nunes (R-Calif.)

H.R.4620: Protecting Families and Small Businesses Act of 2017

Sponsor: Kristi Noem (R-S.D.)

H.R.1625: Consolidated Appropriations Act, 2018

Sponsor: Edward Royce (R-Calif.)

H.R.195: Making further continuing appropriations for the fiscal year ending...

Sponsor: Steve Russell (R-Okla.)

H.R.5795: Overdose Prevention and Patient Safety Act

Sponsor: Earl Blumenauer (D-Ore.)

H.R.6082: Overdose Prevention and Patient Safety Act

Sponsor: Markwayne Mullin (R-Okla.)

H.R.5963: To delay the reimposition of the annual fee on health insurance...

Sponsor: Kristi Noem (R-S.D.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

S.2680: Opioid Crisis Response Act of 2018

Sponsor: Lamar Alexander (R-Tenn.)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

S.684: Middle Class Health Benefits Tax Repeal Act of 2019

Sponsor: Martin Heinrich (D-N.M.)

H.R.1398: Health Insurance Tax Relief Act of 2019

Sponsor: Ami Bera (D-Calif.)

S.172: Health Insurance Tax Relief Act of 2019

Sponsor: Cory Gardner (R-Colo.)

H.R.861: End Surprise Billing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

H.R.2062: Overdose Prevention and Patient Safety Act

Sponsor: Earl Blumenauer (D-Ore.)

S.1012: Protecting Jessica Grubb’s Legacy Act

Sponsor: Joe Manchin III (D-W.Va.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

S.80: Jobs and Premium Protection Act

Sponsor: John Barrasso (R-Wyo.)

H.R.1034: Phair Pricing Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.640: Phair Pricing Act of 2019

Sponsor: John Kennedy (R-La.)

H.R.803: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Peter Welch (D-Vt.)

H.R.1035: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.657: A bill to amend title XXVII of the Public Health Service Act to...

Sponsor: Mike Braun (R-Ind.)

H.R.2115: Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Sponsor: Abigail Spanberger (D-Va.)

H.R.2113: Prescription Drug STAR Act

Sponsor: Richard E. Neal (D-Mass.)

S.1384: Prescription Drug Rebate Reform Act of 2019

Sponsor: Mitt Romney (R-Utah)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3502: Protecting People From Surprise Medical Bills Act

Sponsor: Raul Ruiz (D-Calif.)

H.R.3630: No Surprises Act

Sponsor: Frank Pallone (D-N.J.)

H.R.5800: Ban Surprise Billing Act

Sponsor: Robert C. Scott (D-Va.)

H.R.6379: Workforce Emergency Response Act of 2020

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.6810: Health Care Protection Act

Sponsor: Rodney Davis (R-Ill.)

H.R.6514: Worker Health Coverage Protection Act

Sponsor: Robert C. Scott (D-Va.)

H.R.2328: Reauthorizing and Extending America’s Community Health Act

Sponsor: Tom O'Halleran (D-Ariz.)

H.R.6395: William M. (Mac) Thornberry National Defense Authorization Act for...

Sponsor: Adam Smith (D-Wash.)

S.4049: National Defense Authorization Act for Fiscal Year 2021

Sponsor: James M. Inhofe (R-Okla.)

H.R.6561: Improving Social Determinants of Health Act of 2020

Sponsor: Nanette Barragán (D-Calif.)

S.4440: Improving Social Determinants of Health Act of 2020

Sponsor: Tina Smith (D-Minn.)

H.R.7659: Ensuring Parity in MA for Audio-Only Telehealth Act of 2020

Sponsor: Terri Sewell (D-Ala.)

H.R.6644: To require group health plans and health insurance issuers offering...

Sponsor: Kim Schrier (D-Wash.)

S.3741: Health Care at Home Act of 2020

Sponsor: Tina Smith (D-Minn.)

H.R.7839: Continuing Access to In-Home IVIG Act

Sponsor: Doris Matsui (D-Calif.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

S.4840: Ensuring Parity in MA for Audio-Only Telehealth Act of 2020

Sponsor: Pat Roberts (R-Kan.)

H.R.3107: Improving Seniors' Timely Access to Care Act of 2019

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.1319: American Rescue Plan Act of 2021

Sponsor: John Yarmuth (D-Ky.)

H.R.2166: Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021

Sponsor: Terri Sewell (D-Ala.)

S.150: Ensuring Parity in MA for Audio-Only Telehealth Act of 2021

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.1332: Telehealth Modernization Act

Sponsor: Buddy Carter (R-Ga.)

S.368: Telehealth Modernization Act

Sponsor: Tim Scott (R-S.C.)

S.1512: CONNECT for Health Act of 2021

Sponsor: Brian Schatz (D-Hawaii)

H.R.4074: Addressing Social Determinants in Medicare Advantage Act of 2021

Sponsor: Gus Bilirakis (R-Fla.)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2164: Lower Costs, More Cures Act of 2021

Sponsor: Michael D. Crapo (R-Idaho)

H.R.2608: Ensuring Seniors Access to Local Pharmacies Act of 2021

Sponsor: Peter Welch (D-Vt.)

H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021

Sponsor: David McKinley (R-W.Va.)

H.R.3173: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.4350: National Defense Authorization Act for Fiscal Year 2022

Sponsor: Adam Smith (D-Wash.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.3554: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Peter Welch (D-Vt.)

S.1909: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Jon Tester (D-Mont.)

H.R.6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

Sponsor: Angie Craig (D-Minn.)

S.3700: Affordable Insulin Now Act

Sponsor: Raphael Warnock (D-Ga.)

S.3593: Telehealth Extension and Evaluation Act

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.7666: Restoring Hope for Mental Health and Well-Being Act of 2022

Sponsor: Frank Pallone (D-N.J.)

H.R.7780: Mental Health Matters Act

Sponsor: Mark DeSaulnier (D-Calif.)

S.4293: Pharmacy Benefit Manager Transparency Act of 2022

Sponsor: Maria Cantwell (D-Wash.)

S.3018: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Roger Marshall (R-Kan.)

H.R.7776: James M. Inhofe National Defense Authorization Act for Fiscal Year 2023

Sponsor: Peter A. DeFazio (D-Ore.)

S.113: Prescription Pricing for the People Act of 2023

Sponsor: Charles E. Grassley (R-Iowa)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

S.1001: Telehealth Expansion Act of 2023

Sponsor: Steve Daines (R-Mont.)

H.R.2670: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Mike D. Rogers (R-Ala.)

S.2226: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Jack Reed (D-R.I.)

S.727: Insulin for All Act of 2023

Sponsor: Bernard Sanders (ID-Vt.)

S.1269: INSULIN Act of 2023

Sponsor: Jeanne Shaheen (D-N.H.)

S.146: Cap Insulin Prices Act

Sponsor: Joshua Hawley (R-Mo.)

H.R.1488: Affordable Insulin Now Act

Sponsor: Angie Craig (D-Minn.)

H.R.1587: Making Insulin Affordable for All Children Act

Sponsor: Greg Landsman (D-Ohio)

H.R.1485: Insulin for All Act of 2023

Sponsor: Cori Bush (D-Mo.)

S.2840: Bipartisan Primary Care and Health Workforce Act

Sponsor: Bernard Sanders (ID-Vt.)

S.1967: PBM Act

Sponsor: Robert Menendez (D-N.J.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.5376: Share the Savings with Seniors Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

H.R.5385: Medicare PBM Accountability Act

Sponsor: Greg Landsman (D-Ohio)

H.R.4881: To amend title XVIII of the Social Security Act to limit cost sharing...

Sponsor: Nicole Malliotakis (R-N.Y.)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

S.1542: DRUG Act

Sponsor: Roger Marshall (R-Kan.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

H.R.2666: MVP Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.3561: PATIENT Act of 2023

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.2691: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.3281: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.3285: Fairness for Patient Medications Act

Sponsor: Morgan Griffith (R-Va.)

H.R.3262: To amend title XI of the Social Security Act to increase transparency of...

Sponsor: Jan Schakowsky (D-Ill.)

H.R.3290: To amend title III of the Public Health Service Act to ensure...

Sponsor: Larry Bucshon (R-Ind.)

H.R.3284: Providers and Payers COMPETE Act

Sponsor: Michael C. Burgess (R-Texas)

S.2405: Strengthening Pharmacy Access for Seniors Act

Sponsor: John Thune (R-S.D.)

S.2254: Medicare PBM Accountability Act

Sponsor: Catherine Cortez Masto (D-Nev.)

S.2052: Protect Patient Access to Pharmacies Act

Sponsor: Jon Tester (D-Mont.)

H.R.4822: Health Care Price Transparency Act of 2023

Sponsor: Jason Smith (R-Mo.)

H.R.4508: Hidden Fee Disclosure Act of 2023

Sponsor: Joe Courtney (D-Conn.)

H.R.4507: Transparency in Coverage Act of 2023

Sponsor: Robert Good (R-Va.)

H.R.4895: Lowering Drug Costs for American Families Act

Sponsor: Frank Pallone (D-N.J.)

H.R.5378: Lower Costs, More Transparency Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.4527: Health DATA Act of 2023

Sponsor: Lori Chavez-DeRemer (R-Ore.)

S.464: No Tax Subsidies for E-Cigarette and Tobacco Ads Act

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.2630: Safe Step Act

Sponsor: Brad Wenstrup (R-Ohio)

S.3393: SUPPORT for Patients and Communities Reauthorization Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.3282: Promoting Transparency and Healthy Competition in Medicare Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.5393: To amend title XVIII of the Social Security Act to ensure fair...

Sponsor: Morgan Griffith (R-Va.)

H.R.5372: Expanding Seniors' Access to Lower Cost Medicines Act of 2023

Sponsor: John Joyce (R-Pa.)

H.R.1352: Increasing Access to Biosimilars Act of 2023

Sponsor: Richard Hudson (R-N.C.)

H.R.5386: Cutting Copays Act

Sponsor: Morgan McGarvey (D-Ky.)

H.R.6283: DRUG Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

H.R.269: To authorize an additional district judgeship for the district of Idaho.

Sponsor: Mike Simpson (R-Idaho)

S.2436: NO PBMs Act

Sponsor: Joe Manchin III (D-W.Va.)

S.2973: Modernizing and Ensuring PBM Accountability Act

Sponsor: Ron Wyden (D-Ore.)

S.954: Affordable Insulin Now Act of 2023

Sponsor: Raphael Warnock (D-Ga.)

H.R.1843: Telehealth Expansion Act of 2023

Sponsor: Michelle Steel (R-Calif.)

H.R.824: Telehealth Benefit Expansion for Workers Act of 2023

Sponsor: Tim Walberg (R-Mich.)

S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Sponsor: Ron Wyden (D-Ore.)

S.2406: PBM Oversight Act of 2023

Sponsor: Thomas R. Carper (D-Del.)

S.3548: Health Care Prices Revealed and Information to Consumers Explained...

Sponsor: Mike Braun (R-Ind.)

H.R.3008: Drug Shortage Prevention Act of 2023

Sponsor: Sara Jacobs (D-Calif.)

H.R.3810: Drug Origin Transparency Act of 2023

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.3793: Ensuring Access to Lifesaving Drugs Act of 2023

Sponsor: Elissa Slotkin (D-Mich.)

H.R.167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023

Sponsor: Morgan Griffith (R-Va.)

H.R.6986: To address patent thickets.

Sponsor: Jodey Arrington (R-Texas)

S.3583: A bill to address patent thickets.

Sponsor: Peter Welch (D-Vt.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Heather Podesta	Counsel, Representative Robert Matsui; Counsel, Representative Earl Pomeroy; Legislative Fellow, Senator Bill Bradley; Research Assistant, Congressional Budget Office
Benjamin Klein	Legislative Director, Senator Byron Dorgan; Legislative Assistant, Senator Byron Dorgan Legislative Director, Senator Byron Dorgan (2007-2010); Legislative Assistant, Senator Byron Dorgan (2005-2007)
Jonathan Becker	Chief of Staff, Senator Amy Klobuchar; Chief Counsel, Senator Amy Klobuchar
Stephen Bailey	Sr Tax Csl, Cong Jnt Comm on Deficit Reduction; Sr. Analyst, Revenue/Tax Csl, Sen. Budget Comm.; Leg Asst/ Tax Counsel, Sen. Kent Conrad Senior Tax Counsel, Congressional Joint Committee on Deficit Reduction; Senior Analyst, Revenue/Tax Counsel, Sen. Budget Committee; Legislative Asst/Tax Counsel, Sen. Kent Conrad
Amy Swonger	Whip Liaison, Senator Trent Lott; Dep Asst for Leg Aff, Vice President Dick Cheney; Fl Asst, Senator Mitch McConnell; Legislative Assistant, Senator Trent Lott; Legislative Assistant, Rep. Walter Jones Intern, Rep. Walter Jones Whip Liaison, Senator Trent Lott; Dep Asst for Leg Aff, Vice President Dick Cheney; Fl Asst, Senator Mitch McConnell; Legislative Assistant, Senator Trent Lott; Legislative Assistant, Rep. Walter Jones; Intern, Rep. Walter Jones
Annie Palisi	Chief of Staff, Diane Black; Deputy Director of Member Services, Speaker John Boehner; Director Special Projects, Education and the Workforce Committee
Steve Bailey	Sr Tax Csl, Cong Jnt Comm on Deficit Reduction; Sr Analyst, Revenue/Tax Csl, Sen. Budget Comm.; Leg Asst/ Tax Counsel, Sen. Kent Conrad
Larissa Martinez	Executive Director and Senior Policy Advisor, Senator Deb Fischer; Legislative Assistant, Senator Chuck Hagel; Legislative Correspondent, Representative Nathan Deal; Assistant Scheduler, Senator Johnny Isakson
Stacy Stordahl	Sr Policy Adv, Senate Special Comm on Aging Legislative Director, Rep. Betty McCollum Senior Legislative Asst, Rep. Tammy Baldwin Legislative Assistant, Rep. Ron Kind Staff Assistant, Senator Donald Riegle, Jr. Sr Advisor, Senate Special Comm on Aging
Julian A. Haywood	Staff Dir/Counsel, House Govt Reform Subcomm Min Counsel, House Govt Reform Comm Counsel,House Comm on Stds of Official Conduct Legislative Assistant & Counsel, Rep. Steny Hoyer Legislative Assistant, Rep. Julian Dixon
Katie Wise	Leg. Dir, Rep. Vern Buchanan (2014-2015) Leg. Dir, Rep. Mike Fitzpatrick (2013-2014) Sr. Legislative Asst, Rep. Mike Fitzpatrick (2011-2013) Legislative Correspondent/Asst, Rep. Mary Fallin (2010-2011) Staff Asst, Rep. Mary Fallin (2009-2010)
Lindley Kratovil Sherer	Chief/Staff, Rep. Elise Stefanik (2015-2018); Leg Dir, Rep. Scott Tipton (2013-2014); Leg Dir, Rep. Todd Rokita (2011-2013); Spec Adv, Treas Dept (2007-2008); Spec Asst, Exec Off. of the Pres (2005-2006); Spec Asst, Off. of the VP (2002-2005)
Lindley Sherer	Chief/Staff, Rep. Elise Stefanik (2015-2018); Leg Dir, Rep. Scott Tipton (2013-2014); Leg Dir, Rep. Todd Rokita (2011-2013); Spec Adv, Treas Dept (2007-2008); Spec Asst, Exec Off. of the Pres (2005-2006); Spec Asst, Off. of the VP (2002-2005)
Annabell McWherter	Counsel, U.S. Senate Committee on Veterans Affairs, Senator Johnny Isakson (2018-2020); Law Clerk, U.S. Senate Committee on Veterans Affairs, Senator Johnny Isakson (2018-2018)
Joel Richard	Senior Counsel, Rep. Ted Deutch (2017 - 2021); Legislative Assistant/Counsel, Rep. Ted Deutch (2013 - 2017); Legislative Fellow, Rep. Ted Deutch (2012 - 2013)
Jessica Hatcher	Leg. Dir, Rep. Jake Auchincloss (2021-2023); Sr. Legislative Asst, Rep. Pramila Jayapal (2020); Leg. Asst, Rep. Pramila Jayapal (2018-2020)
Drew Griffin	Chief of Staff, Rep. Robert Latta (2019-2022); Comms Dir, Rep. Robert Latta (2016-2019); Press Sec, Rep. Erik Paulsen (2014-2016); Press Sec, Rep. Jaime Herrera Beutler (2013-2014); Staff Asst, Rep. Jaime Herrera Beutler (2011-2013)
Quincy Enoch	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

1st Quarter, 2024

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 21. Original Filing: 301569234.xml

Lobbying Issues

Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program

Agencies Lobbied

Type of Issue

Lobbying Issues

Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.

Agencies Lobbied

Type of Issue

Lobbying Issues

Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 17. Original Filing: 301526200.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Educare policymakers on issues related to the Improving Seniors Timely Access to Care Act of 2021; S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes; Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act (Reps. Griffith and Carter); H.R. 5372, the Expanding Seniors Access to Lower Cost Medicines Act of 2023; H.R. 1352, the Increasing Access to Biosimilars Act; H.R. 5386, the Cutting Copays Act; and S. the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act).

Agencies Lobbied

Type of Issue

Lobbying Issues

Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modernizing and Ensuring PBM Accountability Act; Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0).

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 19, 2023. Original Filing: 301509258.xml

Lobbying Issues

Educate policymakers on pharmacy issues related to TRICARE and H.R.2670, S.2226 Fiscal Year 2024 National Defense Authorization Act; issues related to P.L 117-328, the Consolidated Appropriations Act 2023, including telehealth and redeterminations; issues related to P.L 117-169, the Inflation Reduction Act of 2022, including enhanced advance premium tax credits (APTCs) and Medicare Part D redesign; issues related to removing barriers to biosimilar medicine access; issues related to insulin pricing, including S. 727, Insulin for All Act of 2023; S. 1269, INSULIN Act of 2023; S. 146, Cap Insulin Prices Now Act of 2023; HR 1488, Affordable Insulin Now Act; HR 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; issues related to mental health coverage, workforce, and mental health parity and the Behavioral Health Network and Directory Improvement Act and S. 2840, Bipartisan Primary Care and Health Workforce Act; and issues related commercial insurance, telehealth, and pharmacy benefits.

Agencies Lobbied

Type of Issue

Lobbying Issues

Educare policymakers on issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule; issues related to S.1967, the Patients Before Middlemen (PBM)Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; issues related to pharmaceutical affordability and access in Medicare under H.R.2880, the Protecting Patients Against PBM Abuses Act; H.R.5376, the Share the Savings with Seniors Act; H.R.5385, the Medicare PBM Accountability Act; and H.R. 4881, and issues related to point-of-sale rebates in Part D LIS under the Medicare program

Agencies Lobbied

Type of Issue

Lobbying Issues

Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127,the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the DRUG Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients(MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262,To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of th e 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; and issues related to Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for SeniorsAct; S.2254,the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822,the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disdosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health DATA Act;H.R. 4508, Hidden Fee Disdosure Act; H.R.3285 - Fairness for Patient Medications Act; S. Modernizing and Ensuring PBM Accountability Act.

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on July 20, 2023. Original Filing: 301486134.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 18, 2023. Original Filing: 301455788.xml

Lobbying Issues

Issues related to S. 113, the Prescription Pricing for the People Act, and S. 127, the Pharmacy Benefit Manager Transparency Act. Issues related to insulin pricing. Issues related to mental health coverage, workforce, and mental health parity. S. 1001, issues related to the Telehealth Expansion Act. Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Mediaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 19, 2023. Original Filing: 301433198.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 20, 2022. Original Filing: 301413538.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on July 20, 2022. Original Filing: 301389566.xml

Lobbying Issues

Inform policymakers on issues related to P.L. 117-103, the Consolidated Appropriations Act, 2022; Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; Issues related to mental health parity in H.R. 5376 Build Back Better Act; Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022; Issues related to H.R. 7780, the Mental Health Matters Act; Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021; Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation; HR. 6833/S. 3700, the Affordable Insulin Now Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Inform policymaker on issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule; Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices; S. 3593, Telehealth Extension and Evaluation Act.

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 18, 2022. Original Filing: 301359059.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 20, 2022. Original Filing: 301332470.xml

Lobbying Issues

Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021; Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation; July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 20, 2021. Original Filing: 301308016.xml

Lobbying Issues

Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions; issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts; issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act; issues related to the Improving Health Care Affordability Act; issues related to the Build Back Better Act, budget reconciliation legislation; June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First."

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 2166/S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act of 2021; H.R. 2846, the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021; H.R. 4074 - To expand the availability of supplemental benefits to certain Medicare Advantage enrollees; H.R.3173, the Improving Seniors Timely Access to Care Act of 2021; issues related to Pharmacy Direct and Indirect Remuneration (DIR); policies that impact public programs payments for high cost drugs including gene therapies; proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices; policies that impact Medicare vision, dental, and hearing benefits.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on July 20, 2021. Original Filing: 301284630.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 20, 2021. Original Filing: 301265378.xml

Lobbying Issues

Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021; issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts; issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 21, 2021. Original Filing: 301244531.xml

Lobbying Issues

Monitor issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, the Protecting People from Surprise Medical Bills Act; H.R. 2328, the Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, the No Surprises Act; and H.R. 5800, the Ban Surprise Billing Act; issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing and transparency and information sharing in the individual and commercial markets; issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency; issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act; issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Monitor H.R. 7659 / S. 4840, the Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes; issues related to prior authorization and utilization management, H.R. 3107, the Improving Seniors' Timely Access to Care Act of 2019; issues related to Pharmacy Direct and Indirect Remuneration (DIR); H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act; proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices; issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 20, 2020. Original Filing: 301217808.xml

Lobbying Issues

Monitor issues related to telehealth during the COVID-19 emergency; issues related to H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act); issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, the Protecting People from Surprise Medical Bills Act; H.R.2328, the Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, the No Surprises Act; and H.R. 5800, the Ban Surprise Billing Act; issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Response, and Economic Security Act (CARES Act); and H.R. 6379, the Take Responsibility for Workers and Families Act; issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing and transparency and information sharing in the individual and commercial markets; issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts; H.R. 6561/S. 4440, the Improving Social Determinants of Health Act of 2020; the Healthcare, Economic Assistance, Liability, And Schools (HEALS Act); the July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay; and the June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on July 20, 2020. Original Filing: 301197770.xml

Lobbying Issues

Monitor issues related to telehealth during the COVID-19 emergency; issues related to H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act); issues related to H.R. 6810, the Health Care Protection Act, H.R. 6379, the Take Responsibility for Workers and Families Act, and H.R. 6514, the Worker Health Coverage Protection Act; issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act; issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act; issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets; issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 20, 2020. Original Filing: 301178313.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 21, 2020. Original Filing: 301128272.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 21, 2019. Original Filing: 301074883.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on July 22, 2019. Original Filing: 301057208.xml

Lobbying Issues

Monitor issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. Educate policymakers on issues related to H.R. 861, the End Surprise Billing Act, and "No Surprises Act" Discussion Draft; issues related to 42 C.F.R. Part 2, H.R. 2062, the Overdose Prevention and Patient Safety Act, and S. 1012, the Protecting Jessica Grubb's Legacy Act; issues related to S. 1895, the Lower Health Care Costs Act, including surprise billing, and transparency and information sharing in the individual and commercial markets.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Educate policymakers on issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs; and proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, and closing the Part D coverage gap and direct negotiation of prescription drug prices. Monitor issues related to Pharmacy Direct and Indirect Remuneration (DIR), including H.R. 1034 / S. 640, the Phair Pricing Act of 2019, H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act, and H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act; and issues related to Medicare Part B reforms, including S. 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S. 657, the Drug Price Transparency Act; and H.R. 2115, the Public Disclosure of Drug Discounts Act. Monitor H.R. 2113, Prescription Drug STAR Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on April 22, 2019. Original Filing: 301035947.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Amendment

Invariant LLC amended a lobbying report for representation of CIGNA Corporation in Q42018 on July 19, 2019. Original Filing: 301052908.xml

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act, and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans. 21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Jan. 22, 2019. Original Filing: 301016192.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $90,000. The report was filed on Oct. 22, 2018. Original Filing: 300995547.xml

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act, and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, non-discrimination provisions, the high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax, H.R. 4620, regarding relief from the Health Insurance Tax, Substance use disorders, and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), and H.R. 6, the SUPPORT for Patients and Communities Act. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on July 20, 2018. Original Filing: 300975180.xml

Lobbying Issues

Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, Invariant LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on April 20, 2018. Original Filing: 300956610.xml

Lobbying Issues

Issues relating to: P.L. 111-148, the Patient Protection and Affordable Care Act; P.L. 111-152, the Health Care and Education Reconciliation Act; H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions; the high-cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017; H.R. 4616, regarding a one-year delay of the Cadillac Tax; H.R. 4620, regarding relief from the Health Insurance Tax; substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act); and H.R. 1625, the Consolidated Appropriations Act of 2018.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, Invariant LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on Jan. 22, 2018. Original Filing: 300935983.xml

Lobbying Issues

Monitor issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions; monitor the high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax; monitor H.R. 4620, the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax; monitor issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models, substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, the Overdose Prevention and Patient Safety Act, and S. 1850, Protecting Jessica Grubbs Legacy Act.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, Invariant LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on Oct. 20, 2017. Original Filing: 300915992.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, Invariant LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on July 20, 2017. Original Filing: 300896673.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, Invariant LLC (formerly known as Heather Podesta + Partners, LLC) lobbied for CIGNA Corporation, earning $80,000. The report was filed on April 20, 2017. Original Filing: 300875422.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on Jan. 23, 2017. Original Filing: 300858442.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on Oct. 20, 2016. Original Filing: 300835715.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on July 20, 2016. Original Filing: 300819517.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on April 20, 2016. Original Filing: 300802659.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $80,000. The report was filed on Jan. 20, 2016. Original Filing: 300781016.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 20, 2015. Original Filing: 300760467.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Registration

1st Quarter, 2013

Termination

Heather Podesta + Partners, LLC terminated an engagement in which they represented CIGNA Corporation on April 19, 2013. Original Filing: 300556705.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Jan. 22, 2013. Original Filing: 300538087.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 18, 2012. Original Filing: 300511351.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on July 19, 2012. Original Filing: 300492321.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on April 19, 2012. Original Filing: 300467854.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Jan. 20, 2012. Original Filing: 300451601.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 20, 2011. Original Filing: 300424347.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on July 20, 2011. Original Filing: 300403838.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on April 15, 2011. Original Filing: 300365108.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Jan. 20, 2011. Original Filing: 300348180.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 15, 2010. Original Filing: 300314235.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on July 20, 2010. Original Filing: 300297139.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on April 19, 2010. Original Filing: 300264174.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Jan. 19, 2010. Original Filing: 300238079.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 19, 2009. Original Filing: 300213382.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on July 20, 2009. Original Filing: 300187052.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on April 20, 2009. Original Filing: 300157750.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Jan. 15, 2009. Original Filing: 300120753.xml

Lobbying Issues

H.R. 2406, Healthcare Information Technology Enterprise Integration Act, as it relates to the establishment of a single standard for health information technology systems used by health providers S. 1693, Wired for Health Care Quality Act, as it pertains to the adoption of a nationwide health information system H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act of 2007, as it pertains to health insurance regulationsS. 558, Mental Health Parity Act of 2007, as it pertains to health insurance regulations H.R. 6357, to amend the Public Health Service Act to promote the adoption of health information technology, as it pertains to the adoption of a nationwide health information system S. 334, Healthy Americans Act, as it pertains to employer-administered health insurance H.R. 1424, Emergency Economic Stabilization Act of 2008, as it pertains to mental health parity H.R. 6049, Renewable Energy and Job Creation Act of 2008, as amended by the Senate on September 23rd, as it relates to mental health parity H.R. 7327, The Worker, Retiree, and Employer Recovery Act of 2008, as it relates to pension reform

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on Oct. 16, 2008. Original Filing: 300093969.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on July 18, 2008. Original Filing: 300073613.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, Heather Podesta + Partners, LLC lobbied for CIGNA Corporation, earning $60,000. The report was filed on April 18, 2008. Original Filing: 300042727.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed